Envestnet Asset Management Inc. Boosts Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Envestnet Asset Management Inc. increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 111,498 shares of the medical equipment provider’s stock after acquiring an additional 356 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Lantheus were worth $8,952,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. Silverberg Bernstein Capital Management LLC grew its position in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after acquiring an additional 100 shares during the period. Moody National Bank Trust Division grew its position in shares of Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after buying an additional 162 shares in the last quarter. Shaker Investments LLC OH raised its holdings in shares of Lantheus by 0.7% in the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after purchasing an additional 182 shares in the last quarter. NBC Securities Inc. lifted its holdings in Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 191 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Activity

In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Performance

Shares of LNTH stock opened at $107.36 on Friday. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a market cap of $7.44 billion, a PE ratio of 16.39 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The company’s fifty day simple moving average is $104.45 and its 200-day simple moving average is $85.69.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.40 EPS. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the subject of several research reports. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Truist Financial lowered their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Finally, Leerink Partners upped their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.